A clinical-biomarker fusion model for risk prediction of coronary artery lesions in Kawasaki disease
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
OBJECTIVE: This study aimed to develop and validate a predictive model integrating multidimensional clinical indicators and laboratory biomarkers for the early and precise assessment of coronary artery lesion (CAL) risk in Kawasaki disease. METHODS: A retrospective analysis was conducted on 320 children with Kawasaki disease admitted between January 2020 and June 2024. The sample size was calculated using PASS 2021 software (α = 0.05, 1-β = 80%), with post-hoc power exceeding 85%. Patients were randomly allocated into a training set (n = 224) and a validation set (n = 96) in a 7:3 ratio. In the training set, univariate analysis identified CAL-associated indicators (P < 0.05). Least Absolute Shrinkage and Selection Operator (LASSO) regression was used for variable compression and feature selection. The core variables were incorporated into a multivariate logistic regression to identify independent risk factors. Based on these factors, three machine learning models—Gradient Boosting Machine (GBM), Support Vector Machine (SVM), and Convolutional Neural Network (CNN)—were constructed. Model performance was evaluated using the AUC, calibration curves, and DCA. Interpretability was analyzed using SHapley Additive exPlanations (SHAP) values. RESULTS: No significant differences in baseline characteristics were observed between the training and validation sets (P > 0.05). Univariate analysis identified seven significant indicators. LASSO regression refined these to five core variables. Multivariate logistic regression confirmed all five as independent risk factors for CAL (P < 0.05). Among the machine learning models, the GBM model demonstrated superior performance, with AUC of 0.872 (95% CI: 0.798–0.945) in the training set and 0.790 (95% CI: 0.623–0.957) in the validation set. Calibration curves were closest to the ideal line. DCA indicated net clinical benefit across a wide threshold probability range. SHAP analysis provided intuitive prediction interpretability. CONCLUSION: An integrated clinical-biomarker model was developed and validated for the early prediction of CAL in Kawasaki disease. The model demonstrates good discriminative ability, calibration, and clinical utility. and provides a promising tool for the early identification of high-risk children and the optimization of intervention strategies. CLINICAL TRIAL NUMBER: Not applicable.
Fields of Study & Subjects
Kawasaki Disease and Coronary Complications
Autoimmune and Inflammatory Disorders Research
Artificial Intelligence in Healthcare
Publication details
- Journal / source
- The Italian Journal of Pediatrics/Italian journal of pediatrics
- Volume
- 52
- Issue
- 1
- Pages
- 85
- Publication date
- 31 March 2026
- Language
- EN